Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 10/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 2/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111256 | 1.00 | ACSS2 (0.42) | ACSS2ADORA1MT-CO1MT-CO2LMNA | |
| SCHEMBL20110992 | 0.92 | ACSS2 (0.40) | ACSS2ADORA1LMNASMN1; SMN2EGFR | |
| SCHEMBL18779254 | 0.92 | ACSS2 (0.40) | ACSS2ADORA1LMNASMN1; SMN2EGFR | |
| SCHEMBL17586626 | 0.85 | ACSS2 (0.38) | ACSS2ADORA1LMNASMN1; SMN2EGFR | |
| SCHEMBL18779239 | 0.83 | ACSS2 (0.36) | ACSS2MT-CO1MT-CO2LMNASMN1; SMN2 | |
| SCHEMBL18791650 | 0.83 | ACSS2 (0.38) | ACSS2ADORA1LMNASMN1; SMN2NR3C2 | |
| SCHEMBL20111103 | 0.83 | ACSS2 (0.38) | ACSS2ADORA1LMNASMN1; SMN2NR3C2 | |
| SCHEMBL17582855 | 0.82 | ITK (0.36) | ACSS2ADORA1LMNASMN1; SMN2EGFR | |
| SCHEMBL21354556 | 0.82 | ACSS2 (0.42) | ACSS2 | |
| SCHEMBL17582851 | 0.82 | ITK (0.36) | ACSS2ADORA1LMNASMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ACSS2 2521/4885ADORA1 2887/4885MT-CO1 1380/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | ACSS2 928/4885ADORA1 2180/4885MT-CO1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.